Skip to main content

IBA signs contract with a major U.S. academic medical center to install two Proteus®ONE proton therapy solutions

Written by Customer Service on . Posted in Public Companies.

Louvain-La-Neuve, Belgium, June 08, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the signing of a contract with Duke University Health System for the installation of two Proteus®ONE1 compact proton therapy solutions at the Duke Proton Center in Durham, NC, USA.

The two Proteus®ONE systems will be installed side by side in a configuration designed to maximize clinical availability, operational flexibility, and patient treatment efficiency. As the market-leading compact proton therapy solution, Proteus®ONE is designed to continuously evolve and integrate the latest technological advancements, enabling IBA users to benefit from cutting-edge innovation and adaptable capabilities. The agreement also includes a long-term operation and maintenance services contract provided by IBA.

Duke Health expects to start proton therapy treatments for patients in 2029.

Olivier Legrain, Chief Executive Officer of IBA, commented: “We are proud to expand IBA’s global community of proton therapy users. Our mission is to expand access to advanced proton therapy and continue pushing the boundaries of cancer treatment. We look forward to establishing a national and regional reference center that will help shape the future of proton therapy in North Carolina and beyond.”

Prof. Erik Sulman, MD, Chair of the Department of Radiation Oncology and Interim Executive Director, Duke Cancer Institute, added: “Duke Health is taking an important step toward transforming cancer care across our state. By developing a proton therapy center, we can offer one of the most precise treatments available, helping patients achieve better outcomes with fewer side effects closer to home.” 

The typical end-user price for one Proteus®ONE solution, including a multi-year maintenance contract, ranges between USD 45 and 55 million.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

CONTACTS
Thomas Pevenage
Investor Relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com

1 Proteus®ONE is a brand name of Proteus®235

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.